Intracranial bleeding under vitamin K antagonists or direct oral anticoagulants: results of the RADOA registry.

ABSTRACT:

Background and purpose

The use of direct oral anticoagulants (DOAC) has increased sharply and DOAC are the oral anticoagulant therapy (OAT) of choice for the majority of patients with newly-diagnosed atrial fibrillation. Intracranial hemorrhage is the most severe adverse event of OAT. Systematic data on the course of intracranial hemorrhage under DOAC compared to vitamin K antagonists (VKA) are warranted to enable shared decision making in AF patients needing OAT.

Methods

This is a secondary analysis of the patients with intracranial bleedings from the prospective multicenter emergency department-based RADOA registry, which collected data on patients admitted with major bleeding while taking VKA or DOAC. The primary endpoint was in-hospital mortality until day 30. We evaluat

SUBMITTER: Pfeilschifter W 

PROVIDER: S-EPMC9059415 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature